# Verdict: richter_transformation.md

1. DOSE LEAK: none. Only numeric content in the file is "9 to 12 months" (line 24, median time to BTK-inhibitor discontinuation for transformation — a time-to-event stat, not a dose/mg/AUC/schedule) and "12th ed" in the citation line. No mg, mg/m2, AUC, cycle-day, or numbered-schedule figures present.

2. UNGROUNDED CLAIMS: none found that lack DeVita support or honest labeling.
   - Definition/histology (DLBCL most common, less commonly classic HL), PET-SUV biopsy-targeting rationale, and the fever/weight-loss/rising-LDH/asymmetric-adenopathy presentation all closely track DeVita lines ~267520-267539 and ~281499-281510.
   - "No standard CIT regimen... treatment objective is disease control then alloSCT" (line 9) matches DeVita ~281441-281447 near-verbatim in substance.
   - Treatment-naive-CLL-better-prognosis / possible separate clonal neoplasm / hyper-CVAD, OFAR, R-CHOP-type regimen options (line 10) match DeVita ~281444-281454 (drug-class names only, no doses given — correctly abstracted).
   - AlloSCT as potentially curative consolidation (lines 9, 15) matches DeVita ~281215-281217.
   - BTK-inhibitor discontinuation for transformation, 9-12 month median (line 24) matches DeVita ~280494-280500 exactly, and correctly excludes the unrelated 9-18 month intolerance/infection figure from the same passage.
   - Splenectomy scoped to AIHA/ITP post-steroid-failure, not Richter itself (line 19) matches DeVita ~281455-281458 and is correctly excluded from the Richter pathway.
   - The sidecar is appropriately self-policing: it explicitly flags the Hodgkin-histology regimen choice (line 11) and the second-line/refractory clinical-trial suggestion (line 16) as "general oncology standard, not from DeVita's section on this disease" rather than presenting them as sourced.
   - Draft agent's reported omission of the axicabtagene ciloleucel/CAR-T statistic checks out on independent grep: DeVita ties that CAR-T outcome data (83%/71% ORR/CRR) specifically to chemorefractory transformed follicular lymphoma in the FL "Histologic Transformation" section (~267520-267543), not to CLL/Richter transformation. Correctly left out rather than mislabeled.
   - No fabricated trial names, drug names, or statistics detected; all specific regimen names (hyper-CVAD, OFAR, R-CHOP) and the discontinuation-timing statistic are traceable to the cited chapter.

3. CITATION: present — "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." (line 29), name only, no page numbers. Compliant.

4. VERDICT: CLEAN (ready for R1).
